Collaborations with big biotech and big pharma are on the rise as innovators forge ahead in a challenging economic environment. This growing trend demands creativity and diligent focus on the structure of these agreements to maximize their corporate and product development potential. Panelists will address the following issues and provide case studies that demonstrate how to ensure a successful collaboration:
- Unique arrangement structures at specific product life cycle stages
- Protecting IP
- Avoiding short-term fallout
- The impact of collaboration on future growth and exit strategies
- Strategies from both sides of the agreement: increasing the opportunity for future collaborations
Panelists:
- Richard A. Kaufman, Partner, Foley & Lardner LLP
- Richard Bork, Corporate Patent Counsel, Novo Nordisk
- Tim Opler, Ph.D., Principal, Torreya Partners
- Thomas Beetham, Senior Corporate Counsel, Genzyme
- Michael Lytton, Executive Vice President, Corporate and Business Development, Biogen Idec
Related Insights
21 April 2025
Health Care Law Today
Prescription Drugs: Executive Order Aims to Lower Prices
On April 15, 2025, President Trump signed an executive order (EO) with the aim of reducing the cost of prescription drugs.
21 April 2025
Health Care Law Today
MedTech Round Table: What the Trump Administration Means for Companies and Investors
Foley & Lardner LLP hosted and participated in a MedTech round table of investors and business leaders, including chief executive officers, partners, directors, innovation leads, investment funds managers and partners, and general counsels. There was collective interest in understanding how these MedTech leaders are adjusting to the changing business and regulatory environment under the second Trump administration.
21 April 2025
Labor & Employment Law Perspectives
Supreme Court’s E.M.D. Sales v. Carrera Decision: A Victory for Employers Navigating FLSA Exemptions
In the case at issue, E.M.D. Sales, Inc. v. Carrera, the court clarified the applicable standard of proof, ruling that employers need only demonstrate by a "preponderance of the evidence," the standard used in most civil cases, that an employee qualifies for an FLSA exemption, rather than the higher more stringent "clear and convincing evidence" standard previously applied by the Fourth Circuit Court of Appeals.